B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Mustang Bio (MBIO) on January 8 and set a price target of $13.00. The company’s shares closed last Thursday at $4.71, close to its 52-week high of $4.85.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 34.3% and a 59.1% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
Currently, the analyst consensus on Mustang Bio is a Strong Buy with an average price target of $11.20.
See today’s analyst top recommended stocks >>
Based on Mustang Bio’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $12.95 million. In comparison, last year the company had a GAAP net loss of $10.17 million.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MBIO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm’s products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in New York, NY.
